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M/48F,age:71 + 9 yrs)followedupfmmdischargeupto September30th,
1995(medianfollow-up:18.4months,range:3 daye-4.7yeare).At entry,
61 hadclaudicetionintermittent(Cl),94 criticallimbischemia(painat rest
and/ortrophic lesions,CLI) and 23 isolatedabdominalaorticaneurysms
(AAA).At the end of follow-up,49 deaths(N =41 CV accordingto death
certificate) were recorded,36 (i’s~o) in ptson CLI, 12 (25~o) in Cl and 1
(2%)inAAA(p < OIJOOl).Whencomparedwithsurvivors(n= 129),dead(n
= 49)wereelightlyolder(72 + 9 vs 70 + 9 yrs,p < 0.04),morefrequently
diabetics(38°Avs 22’%.,p < 0.08)withhi~herfibrinogen(459+ 165vs369
+ 127rng/dl,p -=0.0003)and leukocytes(8.4+ 3 vs 7.5 + 2 x IOg/L,p
< 0.03) levels.Sex distribution(i’z~. vs 80Y0males),systolicBP (160&
22 vs 163 & 21 mmHg),total cholesterol(208+ 43 ve 201 & 46 mg/dl),
triglycerides(155+ S3vs 162*71 rn@dl)did notdiffer.Ptswithfibrinogen
levelsin the higherquarlile(>472 mddl, n = 45)diedmorefrequently(40%
vs 17%,p < 0,01) thanthosein the lowerone (<290 m@dl,n = 4S);the
prevalenceof ptson CLI(44%vs3S%),diabetics(30%va 18%)andactual















ever,few atudieshavedeterminedthe prevalenceof aPl in an unselected
populationwithperipheralvaaculardleeaaa(PVD).Weprospectivelystudied
253 consecutivepts with PVD(60 + 11.4years (mean* SD))and 100
matchedcontrols(58.7+ 11.2yeare).Theprevalenceof aPlwas18.2Y0in
pteand9%incontrola(p <0.03, anticsrdioiipinantibodies:lgG:14.2vs7%,
lgM: 3.2 vs 2Y0,lupusanticoagulant:2 vs O%in ptsand controla,respec-
tively).Riskfactorsfor atheroscleroeiawereequallydistributedamongpts
with aPi (aPI+,n = 46) and pts withoutaPl (aPI- n = 207).Angiogrephic
lesionswereaimilarin the 2 groupsexceptfor infrarenalaorticthromlxrais
whichoccurredin 6,5Y0of aPl+and in 1%of aP1- (p = 0.02).A historyof
deepvein thrombosis(10.9vs 3%, p < 0.05),of stroke(11vs 5.3%),of
coronaryartetydisease(32.6vs20.3%),of haaledcancer(8.7vs2.4%,p <
0.05),Iivado(4.3vs 1°%p c 0.05)andRaynaud’sphenomenon(13vs 1%,
p < 0.001)weremorefrequentin aPl+thanaP1-. In multlvariateanalysis,
the presenceof aPl wassignificantlyasmoiatedwith Iivsdo(F = 93.1,p <
0.0001),historyof cancer(F= 19.4,p < 0.0001),of coronswarterydisease
(F= 16, p < 0.0001)and of deepvein thrombosis(F = 6.8, p e 0.01).In










vasadilatationis impairedIn experimentalpulmonaryembolism(PE). To
atudytherelationshipbetweenthedegreeof impairmentandthe severityof
PE,pulmonaryvsaoreactivitywasexaminedinsubmissive(SM;n= 11)and
massive(M;n = 11)PEin 22 mongreldogsby intrapulmonaryinfusionsof
acstylcholine(ACh)and nitroglycerin(TNG).Selectedcine angiogramsof
a segmentalpulmonaryartary(PA)wereobtainedafter infusionof graded
concentrationsof ACh (10-9 to 10-5M) followedby an infusionof TNG
(40pg)intothe PAbeforeandafterPE.Percentchangein PAdiameterwas
meeauredusingquantitativeangiogrephy.Doseresponsecurvesobtained
fmmmeanvaluesforcontrol,SMand M PEwitheachinfusionof ACHand
TNGaredisplayed.ACH-mediatedpulmonaryvasodilatationis impairedin











OurInstitutehasstudiedthe largestnumberof oaseaof Takayasu’sdisease
in India.550 cases(Male:Female= 1:6.4),age rangeS3S years were
studiedfor last 17 yeara(1978-1995).Hospitalrecordawereanalyaedfor
clinicalparameters,echocardiographic,angiographicfindingsandfollow-up
data.5.8Y0patientspresentedwithsymptomaof activediseaseandthe rest
presentedwith featuresof chmfic disease.Baaedon aortogrephy,type-l
aortoarteritiswasseenin 16%,type-nin 8%andtype-ill in 76%.Pulmonary
involvementwasfoundin 36%andcoronatyinvolvementin 10%patienta.
Afterestablishmentof diagnosisandinitialhighdosesteroidtherapy,all
patientsreceivedlowdosesteroid(Prednisolone2.5 mgfdayfor 2-5 years).



















syndromeshas been linkedto the AM peak in prothromboticforceswith
resultingocclusivethrombusformationperhapsat the site of a ruptured
plaque.Indeed,antiplateletagentshavebeenshownto reducetheAMpeak
intheonsetof acutemyocerdialinfarctionin the PhysiciansHealthStudy.
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However,previousstudiessuggesthatcircadianrhythmsofphysiological
processesare lostwithhospitalization- dueto a disruptanceof the normal
sleep-wakeor rest-activitycycles.
To determineif postoppatients(pts) maintainthe circadianvariability
of prothrcmboticforcesand catacholamlnesurgeswith an increasedAM
Incidenceof silentischemia(S1),westudied51ptswithMonaracontinuous
12-leadECGSfor 46 hra after vascularsurgery;drawingblood samples
before(dayO),& 12,24, 36, 48 hm,and7 daysaftersurgery.Timeof day
wasanalyzedas8 hr Intetvals.
r7eauffs:30% had S1within48 hra of surgery.The majority,69%, had
an AM onset (l-9 am) vs 31% expectedif time of onsetwas uniformly
distributedthroughout the day (p < 0.05).Pfswith S1had T plasminogen
activatorinhibitor(PAI-1)(26 V$ 19 rig/ml,p < 0.05)and norepinephrine
(1406vs971pg/ml,p < 0.05)vsptswithoutS1.
Conclusions:Despitehospitalization,surgicalptsmaintaincircadianvari.
abilitywith an AM peak in onsetof postopS1,correlatingwith surgesin










Tostudythe effectof therapywith b-blockerson the parioparativecardiac
mortalityof patientsundergoingmajorvascularsurgery,we retrospectively
studied420 patientsconsecutivelyreferredfor nuclearcardiologytesting
prior to vascularsurgeryat the MassachusettsGeneralHospitai,and the
Universityof Vermontbetween1964and 1991.Therewere 138patients
whoreceivedparioparativeb-blockers(BB)(32.9%).Patientson BEheda
highar inoidenceof angina(40%vs. 16%;p -=0.001)andreversibledefects
‘on preoperativestressthalliumtesting(35%vs. 23%; p = 0.01).Despite
thishigherriskprofile,the cardiacdeathrateperloperativelywasO%for BB
patients,vs.4%for nonb-blocker(NBB)patienta,respectively,(p= 0.019).
Usinga multivariateanalysis,both hx of Ml and presencaof reversible
thalliumdefectswerepredictiveof perioperetlvecardiacdeath(p a 0.001)
(n = 420). In these high risk groupa,b-blockerusa was associatedwith
pmtactionagainstdeath.Ratesof parioparativecardiacdeathamongthoaa




Rev.than.defect 0/46(o%) 6/65(f2%) 0.02





liumdefacteon preopatreaateat.Thiseuggestathatthe associationis due
to protectiveeffectaof BB, ratherthan their associationwith morebenign
comorbidityprofilee.









Baroreffexsensitivity(BRS) isaaeessadby Phenyiephrinetest (PHE)in the
prognosticstratificationof cardiacpatients(pts).Alpha-index(u), a non-
invasivemeasureof the oversilgain of tha haartperiod-artarialpraeaure
relationshipderlvadfromspaetralanalyais,pmvadto providethesamaeeti-





mwasmeasuredaa rootaquareof the ratioRRto SAPvariabilityspectral
power(P):a =(PRH/PSAp)05,whenthemagnitudesquaredcoherence(MSC)
betweenRRandSAPvariabilitywas>0.50 in lowfrequency(0.04-0.15Hz)
(aLF)and high frequency(0.15-0.45Hz) (IYHF)bands;the meana was
mmputadaea = (aLF+ aHF)/2.PHEfollowedimmediately,by at least3
injections:BRSwasmeasuredas slopeof the regressionlinebetweenRR
andSAPchanges(ARWASAP)whenASAP> 15 mmHgand regression
coefficientr >0.70.
Results:
uLF 10.2* 4.0me’mmHg (n=24)
mHF 7.8+ 4.5mrJmmHg (n =33)
d = (aLF + aHF)/2 9.3 * 3.7 ms/mmHg (n=23)
BRS (PHE) S.7+ 4.3mdmmHa (n = 37)
tiLF wasmeasuredin 60%of pts,IXHFin 82%,a in 57%;PHEallowed
to measureBRSIn92%of pts.Weakcorrelationswereobservedbetween
BRS(PHE)andaLF(r= 0.61),crHF(r=0.S3),a (r= 0.67).Ofnote,aLF was
notevaluablein pts with BRS(PHE)<6 m4mmHgor EF < 25%.
Incmncluslon,a measuredover600heartbeatsbyspectralanalysisdid
notprovidethe sameInformationas PHEdid in our CHFpts,A proportion
of pts,with non-assessablea, hada depressedbut measurableresponse























lower lnHFthan patientswithoutCHF (3.73vs 4.16 In me2,p e 0.001).
Adjustadfor age and LVEFby multipleragreaaion,lnHFwas0.37 In ms2
lower,on average,in patientswithCHFthanin patiantawithoutCHF,(p <




CHFis associatedwitha reductionin PSNAavanafteradjuatingfor LVEF.










analysisof variabilityof haartrate (HRV)and eyatolicbloodpreaaurewaa
performedin 12 patientewith CHFat baseline(B) and one (1 mo) and 4
months(4mo)of traatmantwithcarvediiol.Significant(p = 0.007)increaaes
inparasympathetic(pare)tonewerereflectedbyincreasesin highfrequency
HRV(baata/min)2(B: 1.3 x 10-3+ 0.8 x 10-3; 1 mo: 1.9 x 10-3 & 1.0 x
10”3;4 mo:2.2 x 10-3+ 0.7 x 10-s).Sympathetic(symp)tonadecreaaad
